Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hutmacher

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Clinical Ophthalmology (Auckland, N.Z.)|March 4, 2015
Population pharmacokinetics of pegaptanib sodium (Macugen(®)) in patients with diabetic macular edemaAnthony S Basile, Matthew M Hutmacher, Kenneth G Kowalski, et al.
Journal of Clinical Pharmacology|August 14, 2014
Population dose-response analysis of daily seizure count following vigabatrin therapy in adult and pediatric patients with refractory complex partial seizuresJace C Nielsen, Matthew M Hutmacher, David L Wesche, et al.
Journal of Clinical Pharmacology|October 22, 2009
Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongationSunny Chapel, Matt M Hutmacher, George Haig, et al.
Plos One|September 17, 2013
Predicting relapsing-remitting dynamics in multiple sclerosis using discrete distribution models: a population approachNieves Velez de Mendizabal, Matthew M Hutmacher, Iñaki F Troconiz, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 21, 2017
Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body WeightM M Hutmacher, K Papp, S Krishnaswami, et al.
Clinical Pharmacology and Therapeutics|November 19, 2016
Model-Informed Development and Registration of a Once-Daily Regimen of Extended-Release TofacitinibM Lamba, M M Hutmacher, D E Furst, et al.
Arthritis Research & Therapy|July 27, 2014
Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trialsJohn D Isaacs, Andrea Zuckerman, Sriram Krishnaswami, et al.
Psychopharmacology|June 8, 2011
Translational PK-PD modelling of molecular target modulation for the AMPA receptor positive allosteric modulator Org 26576Roberta Bursi, Gul Erdemli, Robert Campbell, et al.
British Journal of Clinical Pharmacology|August 18, 2016
Comparative assessment of clinical response in patients with rheumatoid arthritis between PF-05280586, a proposed rituximab biosimilar, and rituximabJason H Williams, Matthew M Hutmacher, Matthew L Zierhut, et al.
Clinical Pharmacology and Therapeutics|May 25, 2007
Model-based drug developmentR L Lalonde, K G Kowalski, M M Hutmacher, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Clinical Ophthalmology (Auckland, N.Z.)|March 4, 2015
Population pharmacokinetics of pegaptanib sodium (Macugen(®)) in patients with diabetic macular edemaAnthony S Basile, Matthew M Hutmacher, Kenneth G Kowalski, et al.
Journal of Clinical Pharmacology|August 14, 2014
Population dose-response analysis of daily seizure count following vigabatrin therapy in adult and pediatric patients with refractory complex partial seizuresJace C Nielsen, Matthew M Hutmacher, David L Wesche, et al.
Journal of Clinical Pharmacology|October 22, 2009
Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongationSunny Chapel, Matt M Hutmacher, George Haig, et al.
Plos One|September 17, 2013
Predicting relapsing-remitting dynamics in multiple sclerosis using discrete distribution models: a population approachNieves Velez de Mendizabal, Matthew M Hutmacher, Iñaki F Troconiz, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 21, 2017
Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body WeightM M Hutmacher, K Papp, S Krishnaswami, et al.
Clinical Pharmacology and Therapeutics|November 19, 2016
Model-Informed Development and Registration of a Once-Daily Regimen of Extended-Release TofacitinibM Lamba, M M Hutmacher, D E Furst, et al.
Arthritis Research & Therapy|July 27, 2014
Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trialsJohn D Isaacs, Andrea Zuckerman, Sriram Krishnaswami, et al.
Psychopharmacology|June 8, 2011
Translational PK-PD modelling of molecular target modulation for the AMPA receptor positive allosteric modulator Org 26576Roberta Bursi, Gul Erdemli, Robert Campbell, et al.
British Journal of Clinical Pharmacology|August 18, 2016
Comparative assessment of clinical response in patients with rheumatoid arthritis between PF-05280586, a proposed rituximab biosimilar, and rituximabJason H Williams, Matthew M Hutmacher, Matthew L Zierhut, et al.
Clinical Pharmacology and Therapeutics|May 25, 2007
Model-based drug developmentR L Lalonde, K G Kowalski, M M Hutmacher, et al.
Pageof 4